FDA Grants Priority Review for Amivantamab in Head and Neck Cancer Treatment

The FDA has granted Priority Review to Johnson & Johnson's supplemental Biologics License Application for subcutaneous amivantamab (RYBREVANT FASPRO). This designation is for treating adults with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This action could accelerate the availability of a new dual-targeted treatment option for patients with limited alternatives.